annb0t
Top 20
(Changes dateline, adds share movement in paragraph 1 and 3)
Aug 4 (Reuters) - The U.S. health regulator rejected Mesoblast's cell therapy for children under 12 years of age for treating a type of complication that occurs after a stem cell or bone marrow transplant, sending its Australia-listed shares crashing about 58% on Friday.
The U.S. Food and Drug Administration (FDA) required more data to support marketing approval for the company's lead product remestemcel-L, Mesoblast said in a statem...
>>> Read more: UPDATE 1-Mesoblast shares tank after US FDA rejects cell therapy for children
Aug 4 (Reuters) - The U.S. health regulator rejected Mesoblast's cell therapy for children under 12 years of age for treating a type of complication that occurs after a stem cell or bone marrow transplant, sending its Australia-listed shares crashing about 58% on Friday.
The U.S. Food and Drug Administration (FDA) required more data to support marketing approval for the company's lead product remestemcel-L, Mesoblast said in a statem...
>>> Read more: UPDATE 1-Mesoblast shares tank after US FDA rejects cell therapy for children
